关注
Alessia Cimadamore
Alessia Cimadamore
在 uniud.it 的电子邮件经过验证
标题
引用次数
引用次数
年份
Immune checkpoint inhibitors for the treatment of bladder cancer
A Lopez-Beltran, A Cimadamore, A Blanca, F Massari, N Vau, M Scarpelli, ...
Cancers 13 (1), 131, 2021
1322021
Variants and new entities of bladder cancer
A Lopez‐Beltran, V Henriques, R Montironi, A Cimadamore, ...
Histopathology 74 (1), 77-96, 2019
1172019
Epigenetic modulations and lineage plasticity in advanced prostate cancer
R Ge, Z Wang, R Montironi, Z Jiang, M Cheng, M Santoni, K Huang, ...
Annals of Oncology 31 (4), 470-479, 2020
952020
Androgen receptor signaling pathway in prostate cancer: from genetics to clinical applications
G Aurilio, A Cimadamore, R Mazzucchelli, A Lopez-Beltran, E Verri, ...
Cells 9 (12), 2653, 2020
922020
PD-L1 assessment in urothelial carcinoma: a practical approach
M Eckstein, A Cimadamore, A Hartmann, A Lopez-Beltran, L Cheng, ...
Annals of Translational Medicine 7 (22), 2019
802019
Immunotherapy in renal cell carcinoma: latest evidence and clinical implications
M Santoni, F Massari, V Di Nunno, A Conti, A Cimadamore, M Scarpelli, ...
Drugs in Context 7, 2018
712018
Is there a role for immunotherapy in prostate cancer?
A Rizzo, V Mollica, A Cimadamore, M Santoni, M Scarpelli, F Giunchi, ...
Cells 9 (9), 2051, 2020
702020
New prostate cancer targets for diagnosis, imaging, and therapy: focus on prostate-specific membrane antigen
A Cimadamore, M Cheng, M Santoni, A Lopez-Beltran, N Battelli, ...
Frontiers in oncology 8, 653, 2018
662018
Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype
J Rebola, P Aguiar, A Blanca, R Montironi, A Cimadamore, L Cheng, ...
Virchows Archiv 475, 445-455, 2019
452019
The identification of immunological biomarkers in kidney cancers
A Lopez-Beltran, V Henriques, A Cimadamore, M Santoni, L Cheng, ...
Frontiers in Oncology 8, 456, 2018
432018
The human microbiota and prostate cancer: friend or foe?
F Massari, V Mollica, V Di Nunno, L Gatto, M Santoni, M Scarpelli, ...
Cancers 11 (4), 459, 2019
422019
Re: gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
M Santoni, F Piva, A Conti, A Santoni, A Cimadamore, M Scarpelli, ...
European urology 74 (4), 521-522, 2018
412018
The role of obesity in renal cell carcinoma patients: clinical-pathological implications
G Aurilio, F Piva, M Santoni, A Cimadamore, G Sorgentoni, ...
International journal of molecular sciences 20 (22), 5683, 2019
402019
Molecular mechanisms related to hormone inhibition resistance in prostate cancer
V Mollica, V Di Nunno, A Cimadamore, A Lopez-Beltran, L Cheng, ...
Cells 8 (1), 43, 2019
392019
Towards a new WHO classification of renal cell tumor: what the clinician needs to know—a narrative review
A Cimadamore, L Cheng, M Scarpelli, F Massari, V Mollica, M Santoni, ...
Translational Andrology and Urology 10 (3), 1506, 2021
372021
Treating Prostate Cancer by Antibody–Drug Conjugates
M Rosellini, M Santoni, V Mollica, A Rizzo, A Cimadamore, M Scarpelli, ...
International Journal of Molecular Sciences 22 (4), 1551, 2021
342021
RAS genes in colorectal carcinoma: pathogenesis, testing guidelines and treatment implications
O Saeed, A Lopez-Beltran, KW Fisher, M Scarpelli, R Montironi, ...
Journal of clinical pathology 72 (2), 135-139, 2019
322019
Morphologic, molecular and clinical features of aggressive variant prostate cancer
R Montironi, A Cimadamore, A Lopez-Beltran, M Scarpelli, G Aurilio, ...
Cells 9 (5), 1073, 2020
302020
Current and emerging bladder cancer biomarkers with an emphasis on urine biomarkers
A Lopez-Beltran, L Cheng, T Gevaert, A Blanca, A Cimadamore, ...
Expert review of molecular diagnostics 20 (2), 231-243, 2020
292020
Novel therapeutic approaches and targets currently under evaluation for renal cell carcinoma: waiting for the revolution
V Mollica, V Di Nunno, L Gatto, M Santoni, A Cimadamore, L Cheng, ...
Clinical Drug Investigation 39, 503-519, 2019
292019
系统目前无法执行此操作,请稍后再试。
文章 1–20